



Schrepf, A., Moser, S., Harte, S. E., Basu, N., Kaplan, C., Kolarik, E., Tsodikov, A., Brummett, C. M. and Clauw, D. J. (2020) Top down or bottom up? An observational investigation of improvement in fibromyalgia symptoms following hip and knee replacement. *Rheumatology*, 59(3), pp. 594-602. (doi: [10.1093/rheumatology/kez303](https://doi.org/10.1093/rheumatology/kez303))

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/189110/>

Deposited on 26 June 2019

Enlighten – Research publications by members of the University of Glasgow  
<http://eprints.gla.ac.uk>

**Top down or bottom up? An observational investigation of improvement in fibromyalgia symptoms following hip and knee replacement.**

Andrew Schrepf<sup>1</sup>, Stephanie Moser<sup>1</sup>, Steven E. Harte<sup>1</sup>, Neil Basu<sup>2</sup>, Chelsea Kaplan<sup>1</sup>, Ellen Kolarik<sup>1</sup>, Alexander Tsodikov<sup>3</sup>, Chad Brummett<sup>1</sup>, Daniel J. Clauw<sup>1</sup>

<sup>1</sup>Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan, USA

<sup>2</sup> Institute of Infection, Immunity & Inflammation, University of Glasgow, UK

<sup>3</sup>School of Public Health, University of Michigan, Ann Arbor, Michigan, USA

Correspondence to: Andrew Schrepf

Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan Health System, Domino's Farms, Lobby M, PO Box 385, 24 Frank Lloyd Wright Dr., Ann Arbor, MI 48106. Email: [aschrepf@med.umich.edu](mailto:aschrepf@med.umich.edu)

## **ABSTRACT**

**Objectives:** Many patients with osteoarthritis have comorbid symptoms of fibromyalgia (FM), but it unknown how these symptoms respond to surgical procedures that address nociceptive input in the periphery, such as total joint replacement. Here we explore differences in clinical characteristics between patients whose FM symptoms do and do not improve following total hip or knee replacement.

**Methods:** Participants were 150 patients undergoing knee or hip replacement who had a minimum FM survey score of 4 or greater prior to surgery. The top tertile of patients experiencing the most improvement in FM symptoms at month 6 were categorized as 'Improve' (n=48) while the bottom two tertiles were categorized as 'Worsen/Same' (n=102). . Baseline symptom characteristics were compared between groups, as well as improvement in overall pain severity, surgical pain severity and physical function at six months.

**Results:** The Worsen/Same group had higher levels of fatigue, depression, and surgical site pain at baseline (all  $p < 0.05$ ). Additionally, they improved less on overall pain severity and physical functioning six months after surgery (both  $p < 0.05$ ).

**Conclusion:** Most patients derive significant benefit in improvement of comorbid FM symptoms following total joint replacement, but a substantial proportion do not. Understanding the neurobiological basis for these different trajectories may help inform clinical judgment and improve patient care.

**Keywords:** Osteoarthritis; Fibromyalgia; total joint replacement; central sensitization

**Key messages:**

- Most patients with osteoarthritis experience substantial improvement in comorbid fibromyalgia symptoms after total joint replacement.
- A minority of patients with osteoarthritis regress to pre-surgical levels of fibromyalgia symptoms by month six.
- Osteoarthritis patients who show less benefit have higher levels of fatigue and depression before the procedure.

## INTRODUCTION

It is now widely accepted that the symptoms used to define fibromyalgia (FM), such as widespread pain, fatigue, and cognitive dysfunction, are present to some degree in all rheumatic disorders and chronic pain conditions.[1] The level of these symptoms, or the degree of FM symptoms an individual possesses are hypothesized to be associated with aberrant central nervous system mechanisms. This hypothesis is supported by imaging techniques designed to explore the brain's structure, function, and neurochemical features.[2-4] It was recently demonstrated that the degree of FM symptoms (measured on a continuum via the 2011 FM Survey Criteria[5]) in rheumatoid arthritis (RA) correlates with increased connectivity between the insula and Default Mode Network of the brain [6], replicating one of the most salient neurobiological findings in clinical FM populations[7]. These central differences may be why the degree of FM symptoms a patient has prior to surgery is a strong predictor of post-surgical outcomes such as the likelihood of improvement in pain and need for analgesics.[8-11]

It has been hypothesized that comorbid FM symptoms in other rheumatologic conditions may arise through two relatively distinct pathways: 'bottom up' and 'top down' mechanisms of central sensitization.[12] 'Top down' mechanisms of central sensitization refer to pain amplification that exists independent of peripheral inflammation and other nociceptive input. This concept is supported by the frequent disagreement between the degree of damage or inflammation in the joint and the severity of symptoms reported by the patient.[13] These 'top down' mechanisms are believed to be familial and to disproportionately affect females [14, 15].

In an osteoarthritis (OA) patient whose comorbid FM symptoms are driven primarily by ‘top down’ mechanisms surgery should have limited benefit for pain outside the surgical site.

Conversely, in some patients, peripheral sources of nociceptive input such as joint inflammation and damage sensitize the CNS to pain in a ‘bottom up’ fashion. According to this view, chronic injury and/or inflammation, such as that due to OA, drives central nervous system sensitization, resulting in comorbid FM symptoms. Woolf originally advanced the term ‘central sensitization’ to describe this process when spinal and brain mechanisms promote pain at sites distal from the primary injury, damage, or inflammation, a phenomenon well established in animal models.[13] In a patient where comorbid FM symptoms are being driven by chronic nociceptive input in the knee or hip, arthroplasty should improve these symptoms by reducing the source of central sensitization. In fact, a reduction in global pain sensitivity does seem to occur in a subset of individuals receiving lower extremity arthroplasty.[14]

Examining how comorbid FM symptoms change after lower extremity arthroplasty, where the primary source of nociceptive input is removed, allows for a natural experiment to identify phenotypes consistent with ‘bottom up’ versus ‘top down’ mechanisms. Using a cohort of OA patients undergoing hip and knee arthroplasty, we sought to identify different patterns of how FM symptoms change following the procedure, as well as the baseline characteristics associated with these patterns. We also sought to determine if there were marked differences in the temporal pattern of these changes, and if these patterns were associated with different clinical outcomes following surgery.

## METHODS

### *Sample*

The eligible pool of participants were 453 individuals undergoing either knee or hip replacement surgery at Michigan Medicine. These patients were recruited between April, 2015 and November, 2016. The current study was approved by the University of Michigan Institutional Review Board and all participants provided informed consent. Of these, 107 were using opioid medications prior to surgery, which may influence the comorbid symptoms of interest from the 2011 Fibromyalgia Survey Criteria, and were therefore excluded from further analyses. A comparison of symptoms between patients taking/not taking opioids at baseline is shown in Supplementary Table S1, available at *Rheumatology* online. Analyses were restricted to participants showing at least moderate levels of comorbid symptoms prior to surgery as indicated by a 4 or greater on the 2011 criteria; participants with scores below 4, the sample median of patients not taking opioids at baseline, were excluded. Of the remaining 201 participants, 51 did not have data available at the follow up visit (month 6) and were also excluded. This resulted in a final sample of 150 participants. Demographic information is shown in Table 1.

### *Measures*

The 2011 survey criteria for FM was used to assess widespread body pain and comorbid symptoms.[5] The 2011 criteria contains a 19 areas that can be indicated as painful, and several questions about constitutional symptoms such as fatigue, cognitive difficulties, and unrefreshing sleep. These aspects of the centralized pain spectrum can be analyzed separately

as the Widespread Pain Index (WPI) and Symptom Severity Index (SSI). The SSI serves as an index of somatic and constitutional symptoms that are frequently present in FM. A more detailed body map (the Michigan Body Map [MBM][15]) containing 35 sites was administered that includes all the WPI sites, allowing us to calculate the WPI. A non-surgical site pain index was created by removing the bilateral surgical sites from the respective cohorts (hips from the hip cohort, knees from the knee cohort) -- this allows us to examine the impact of the procedure on pain outside the surgical site. Overall pain severity, and surgical site pain severity, was measured by the Brief Pain Inventory (BPI)[16]. The Patient-Reported Outcomes Measurement Information System-Short Forms (PROMIS®-SF) were used to measure depression, anxiety, fatigue, sleep disturbance, and physical function. [17]. Six questions from the catastrophizing subscale from the Coping Strategies Questionnaire (CSQ) were used to measure catastrophic cognitive appraisal of pain[18]. Primary outcomes for baseline analyses were FM survey criteria (WPI and SSI), depression, fatigue, and sleep disturbance. For longitudinal analyses the primary outcomes were change scores in physical function, overall pain severity, and surgical site pain severity. Age, sex, and surgical cohort were examined as potential confounding variables.

### *Group Definitions*

To identify groups that showed different patterns of comorbid symptom change after surgery, we first calculated a simple change score between baseline and month 6 for the 2011 FM survey criteria. We then regressed this change score on the baseline survey score to account for regression to the mean type effects. The resulting residuals were divided into three tertiles by rank values. We compared the proportion of each group who achieved at least a 30%



reduction in FM symptoms by month 6 using Chi-square tests, or Fisher's exact test when expected counts are less than 5, with correction for multiple comparisons. We subsequently combined the top two tertiles into one group (n=102), 'Improve,' for comparison to the bottom tertile, 'Worsen/Same.'

### *Statistical Analyses*

#### Baseline comparisons

Improve versus worsen/same comparisons were made on continuous outcomes by t-test and categorical outcomes by chi-square statistic. Primary outcomes for baseline analyses were FM survey criteria (overall, WPI, and SSI), depression, fatigue, and sleep disturbance. Additionally, anxiety, MBM non-surgical sites, non-surgical and surgical pain severity, as well as age, were compared between groups. Surgical site (hip versus knee), and gender were categorical outcomes. We also compared those patients who were included in the study (with available six-month data; n=150) to those who were lost to follow-up (n=48), on age, gender, surgical site and baseline levels of FM symptoms.

### *Longitudinal analyses*

#### Trajectory of change

The trajectory of change in total 2011 FM Survey Scores, MBM non-surgical site pain (e.g. not surgical hip or knee), and SSI scores were examined in mixed-effect models, with random subject-specific intercept and time effects, using restricted estimation of maximum likelihood.

Both linear and quadratic effects of time were modeled and the primary outcomes of interest were grouped by time interaction terms.

#### Improvement in non-surgical pain and physical function

Primary outcomes were change scores in BPI overall pain severity and PROMIS physical function measures (pre-surgery – month 6 scores). These change scores were then compared between groups in general linear models controlling for baseline scores, participant age, and surgical group.

#### Surgical-site pain after surgery

The primary outcomes was surgical pain (yes/no) was compared between groups at each post-surgical time point, week 2, month 1, month 3, and month 6, by chi-square test.

## RESULTS

### *Group Definitions*

A very small proportion of those patients in the lowest tertile of FM improvement achieved a 30% reduction in FM symptoms (6.3%). Conversely, 89% of those in the middle tertile, and 100% of those in the top tertile achieved 30% improvement. The difference between low and middle tertiles was significant (Chi-square = 68.5;  $p < .001$ ) as was the difference between low and high tertiles (Chi-square = 85.7;  $p < .001$ ). However, there was no statistically significant difference in the proportion of those showing 30% improvement between the middle and high tertiles (Fisher's exact adjusted  $p = .08$ ). These top two tertiles were subsequently combined, as mentioned above.

### *Baseline Comparison*

Age, gender, and surgical cohort did not differ significantly between the groups (all  $p > 0.13$ ; See Table 1). Similarly, there were no significant pre-surgical group differences on painful body sites measured by the WPI or non-surgical sites on the MBM, the SSI, sleep disturbance, physical function, pain catastrophizing, or overall pain severity (all  $p > 0.10$ ). Conversely, total FM survey scores ( $p = 0.045$ ), fatigue ( $p = 0.014$ ), depression ( $p = 0.003$ ), and surgical site pain severity ( $p = 0.032$ ) were elevated in the Worsen/Same group compared to those who improved (See Table 1 for means and SDs by group for each measure).

Those patients who did not have complete six-month data were younger than those who did (mean loss to follow-up = 56.02; SD= 14.33; 95% CI = 51.86, 60.18; mean included = 63.01; SD= 10.08; 95% CI= 61.39, 64.64;  $p < .001$ ). There were no significant differences in baseline FM symptoms (mean loss to follow-up = 7.29; SD= 2.86; 95% CI = 6.46, 8.12; mean included = 7.03; SD= 2.66; 95% CI= 6.60, 7.46;  $p = .57$ ). There were no differences in the proportion of each group having hip replacement (loss to follow-up = 47.9%; included = 56.7%;  $p = .29$ ) or in the proportion of female patients (loss to follow-up = 56.3%; included = 61.3%;  $p = .53$ ).

### *Longitudinal Analyses*

#### Trajectory of change

The effect of time on total FM scores differed substantially by group (time by group interaction,  $p < 0.001$ ). The change over time in MBM non-surgical pain sites (excluding the hip or knee)

and SSI scores also differed by group (time by group interaction, both  $p < 0.001$ ) indicating that both comorbid pain and constitutional symptoms contribute to the different trajectories in total score improvement (See Figure 1 for group trajectories and change in pain distribution over time). In both groups, improvement occurred at the one-month time point, but by month three, the Worsen/Same group showed substantial regression in their symptoms, such that by month six they had returned to pre-surgical levels of FM symptoms. Conversely, the Improve group continued to show benefits at month three and through month six. These non-linear patterns are reflected in the greater deviation from linear change seen in the Worsen/Same group for total FM survey and SSI scores (quadratic effect of time by group interaction, both  $p < 0.05$ ). All model output is shown in Table 2. MBM non-surgical pain and SSI trajectories are shown in Supplementary Figure S1, available at *Rheumatology* online.

#### Improvement in non-surgical pain and physical function

Participants in the Worsen/Same group showed significantly lower levels of improvement in overall pain severity at month 6, after controlling for baseline symptom levels, age, and surgical site ( $p=.004$ ). The estimated improvement in overall pain severity for the Improve group was 2.25 points (95% CI= 1.84, 2.65; S.E.=0.20) or 48% of pre-surgical levels, versus 1.21 points (95% CI= .63, 1.79; S.E. = 0.29) or 25% of pre-surgical levels for the worsen/same group. Similarly, the Worsen/Same group showed significantly less improvement in physical function ( $p= 0.021$ ). The estimated improvement in physical function for the Improve group was 5.66 (95% CI= 2.95, 5.17; S.E.=0.39) or 43% of pre-surgical levels, versus 4.06 (95% CI= 4.89, 6.43; S.E. = 0.56) or 29% of pre-surgical levels for the Worsen/Same group.. In analyses where patients still taking

opioid medications after month 1 were removed, (Worsen/Same n=6 [12.5%], Improve n=4 [3.9%]), the results were similar (data not shown).

#### Improvement in surgical-site pain.

At month 6, there was no difference in the percentage of participants reporting no surgical-site pain (yes/no) between the two groups (Improve = 74%, Worsen/Same = 69%,  $\chi^2=.37$ ; df=1, p = 0.54). Conversely, at week 2 (Improve = 27%, Worsen/Same = 9%,  $\chi^2=5.92$ ; df=1, p = 0.015), month 1 (Improve = 43%, Worsen/Same = 13%,  $\chi^2=12.99$ ; df=1, p < 0.001), and month 3 (Improve = 73%, Worsen/Same = 54%,  $\chi^2=4.71$ ; df=1, p = 0.030), a smaller proportion of participants in the Worsen/Same group reported being pain free at the surgical site. See Figure 2.

## DISCUSSION

These analyses show that the trajectory of change in FM symptoms after joint replacement surgery follow distinct patterns. In most patients, significant improvement in FM symptoms, including multifocal pain and constitutional symptoms, occurs rapidly (i.e. one month) and is maintained through six months following the procedure. The observed improvement in both constitutional symptoms and widespread pain is important as it indicates that this phenomenon is not simply due to improved referred pain or biomechanics following the procedure.

Conversely, approximately one third of patients demonstrate a relatively modest improvement in these symptoms at one month, followed by a reversion to pre-surgical levels by month six, despite improvement in pain at the surgical site. This means that for a subset of OA patients, no long-term benefit for comorbid highly burdensome symptoms like multifocal pain, fatigue, and sleep disruption can be expected, as neither non-surgical site pain or constitutional symptoms improved for the vast majority of this subgroup. These different effects are not due to pre-surgical levels of comorbid FM symptoms, which were controlled for in our analyses.

These phenotypes are consistent with divergent mechanisms in how comorbid symptoms are generated. In a recent series of reviews exploring the neurobiological evidence for central sensitization, Woolf and others advanced two hypothetical subtypes: ‘bottom-up’ and ‘top-down’ central sensitization.[12] [19] For most patients, with what can be called ‘bottom-up’ sensitization, the removal of the primary nociceptive generator reduces FM symptoms, perhaps by attenuating central sensitization. For a substantial minority of patients – the ‘top-down’ phenotype -- the procedure has no long-term benefit for comorbid FM symptoms. Clearly,

these novel distinctions need to be explored further, but in our view they provide a helpful framework for exploring the variability in how OA patients respond to total joint replacement.

There are several important implications of these findings for both the mechanistic understanding of central sensitization in patients undergoing joint replacement procedures and for their clinical care. These findings are foreshadowed to some degree by the neglected concepts of primary and secondary fibromyalgia.[20, 21] In a majority of patients comorbid FM symptoms respond favorably to surgery, suggesting that these symptoms were driven or maintained by nociceptive input in the affected joint. This finding is supported by a previous study indicating that successful OA surgery results in substantial improvement of responses to experimental pain measures outside the surgical site; patients whose surgery eliminated their pain showed a more normal inhibitory response to evoked pain than they did prior to surgery [14]. Animal models have demonstrated convincingly that regional and even widespread hyperalgesia follow localized chronic injury or inflammation such as sciatic constriction or repeated formalin injections – an analog to ‘bottom-up’ sensitization[22] and we have recently shown that peripheral inflammation is associated with profound changes in brain function in RA that promote core symptoms of FM [23]. Together these findings suggest that bottom-up mechanisms are important in rheumatic diseases.

Comparing the locations of pain improvement/non-improvement following surgery shows that in the Improve group, the largest effects are seen the lower body contiguous with or near the site of surgery, with some additional benefits for back pain. Conversely, the Worsen/Same group of patients do not show these effects. These patients showed modest improvement in the lower body, and an overall pattern of worsening in the upper extremities. This is consistent

with some animal models of fibromyalgia wherein removal of nociceptive input in the periphery has no effect on global hyperalgesia once the animal becomes centrally sensitized [24].

Patients in the Worsen/Same group showed worsening of comorbid symptoms at the same time that surgical-site pain seemed to resolve, in contrast with those in the Improve group whose comorbid symptoms and surgical-site pain improved in tandem. Surgical site pain seemed to persist for longer in a larger proportion of patients in the Worsen/Same group. This suggests that the distinction between *peripherally* driven central-sensitization, and *centrally maintained* central-sensitization, is in fact an important one.

The Worsen/Same group of patients showed substantially less improvement in both overall pain severity and functional disability six months after the procedure. This may simply reflect the fact that their comorbid symptoms have not improved, despite comparable levels of surgical-site improvement to the Improve group. Nonetheless, these metrics represent important benchmarks for improvement following joint-replacement. Because surgical site pain improved equally in the two groups, it could fairly be said that a good deal of the overall improvement observed in the Improve group is due to improvement in comorbid symptoms (e.g. fatigue, trouble thinking/remembering), rather than surgical site pain. Clinically, this means that monitoring improvement in symptoms outside the surgical site is important, and should be done in tandem with questions about the severity of pain in the surgical area. It is also critical to monitor these symptoms beyond the first month post-operatively, as both groups appeared to improve at one month, a time when substantial numbers of patients in both groups were still using narcotic analgesics. Furthermore, the difference between patient groups in those reporting surgical site pain was no longer apparent at six months, this suggests



that longer (i.e., at least six months) follow-up may be necessary to identify patients who failed to respond to the procedure in terms of surgical site pain.

These findings raise the critical question of how patient phenotypes might be distinguished prior to surgery. Our analyses were designed to control for pre-surgical levels of fibromyalgia symptoms, so that the trajectory of improvement could be isolated from regression to the mean type effects. Nonetheless, pre-surgical symptom levels revealed higher levels of fatigue, depression, and surgical site pain severity in the Worsen/Same group. These differences were modest and do not appear to lend themselves to forming reliable cutoffs (effect sizes range from 0.35- 0.51).

There are many ways in which these two different subsets of arthroplasty patients might be better differentiated prior to surgery, that we did not measure in this study. For example, individuals with a 'top-down' form of FM that is most commonly studied in mechanistic studies have high rates of co-morbid chronic overlapping pain conditions (COPCs) that typically present earlier in life.[25, 26] Individuals with FM similarly have been repeatedly shown to have much higher rates of mood disorders[27], again supportive of a primary brain mechanism, rather than a peripherally-driven phenomenon. We and others have also shown that individuals with the primary form of FM that occurs without obvious evidence of ongoing nociceptive input display evidence of not only pain sensitivity, but are also much more sensitive to the intensity and unpleasantness of other sensory modalities, such as light and sound, and that this is a critical feature that can correctly classify individuals with FM vs. those without on functional neuroimaging studies.[28-31]

These findings point to the further need for mechanistic studies that explore the neurobiological substrates of patients who show these different trajectories in improvement following conventional peripherally-directed treatments. The clinical impact of better understanding these two subsets is obvious, since the bottom-up subset should benefit from aggressive use of peripherally-directed therapies, including not only appropriate surgery or injections, but also the use of drugs such as the Nerve Growth Factor antibodies that may soon become available, and might be able to eliminate ongoing nociceptive input better than any currently available therapies.[32, 33]

### *Limitations*

We chose our cutoff for inclusion (minimum score of 4) using the distribution of the FM scores in the sample, this decision was still somewhat arbitrary as there are no subclinical cutoffs on the FM survey instrument to define moderate symptoms. Additionally, the loss of approximately 25% of the patient sample at six months represents a potential source of bias. While included patients did not differ on baseline FM symptoms, they were older on average than those lost to follow-up, and therefore these patterns will need to be confirmed in younger patients. No information was collected about the duration of symptoms for either OA or FM, and consequently we cannot define secondary FM in the current sample. The group definitions used here were derived retrospectively and led to differences in subgroup sizes. Future studies may employ a matched design.

Patients undergoing knee and hip replacement show distinct trajectories in how FM symptoms improve, or do not improve, after the procedure. Improvement in comorbid FM symptoms

appears to occur in a substantial number of patients undergoing arthroplasty. These trajectories are related to the overall impact of the procedure on measures of pain and disability after six months. These differences are not readily apparent in symptom phenotyping performed prior to the procedure, but may be revealed through mechanistic phenotyping using neuroimaging and quantitative sensory testing. Future studies will determine if and how these patterns hold in other surgical cohorts with high levels of comorbid FM symptoms.

**Disclosure statement:** DJC reports personal fees from Abbott Pharmaceutical, grants and personal fees from Aptinyx, personal fees from Astellas Pharmaceutical, grants and personal fees from Cerephex, personal fees from Daiichi Sankyo, grants and personal fees from Pfizer, Inc, personal fees from Pierre Fabre, personal fees from Samumed, personal fees from Theravance, personal fees from Tonix, personal fees from Williams & Connolly LLP, and personal fees from Zynerva, outside the submitted work. SEH reports grants from NIH during the conduct of the study; grants from NIH, VA, Cerephex, Eli Lilly, American Cancer Society, AAOFG; grants and personal fees from Aptinyx; personal fees from SUFU, Longitudinal Capital Management; personal fees and nonfinancial support from University of North Carolina, Chapel Hill; and an affiliation with Arbor Medical Innovations, outside the submitted work. In addition, S.E. Harte has a patent US 9307906 with royalties paid outside the submitted work. CB received consultancy fees from Biomet, Inc. and grants from American Society of Regional Anesthesia and Pain Medicine Chronic Pain Research, RO1 AR 060392, and the Michigan Genomics Initiative (unrelated to current work). The other authors have declared no conflicts of interest.

**Funding:** This work was supported by NIH/NIAMS P50 AR070600 and R01 AR060392 (Clauw DJ-Contact; Brummett CM).

**Acknowledgements:** The authors thank the research staff from the Department of Anesthesiology and the surgical teams for their assistance in the success of this study. DJC, SEH and CB designed the research. SM and EK performed the research and data collection. AS and AT analyzed the data. All authors contributed to writing the manuscript. All authors read and approved the final manuscript. Additional support came from NIH/NIDA R01 DA038261 (Clauw, DJ – Contact / Brummett, CM) and K12 DE023574 (Clauw, DJ – Contact/Kapila, SD).

## References

1. Clauw, D.J., *Fibromyalgia: a clinical review*. JAMA., 2014. **311**(15): p. 1547-1555.
2. Harris, R.E., et al., *Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients*. Anesthesiology, 2013. **119**(6): p. 1453-64.
3. Napadow, V. and R.E. Harris, *What has functional connectivity and chemical neuroimaging in fibromyalgia taught us about the mechanisms and management of 'centralized' pain?* Arthritis Res Ther., 2014. **16**(5): p. 425.
4. Schrepf, A., et al., *Endogenous Opioidergic Dysregulation of Pain in Fibromyalgia: a PET and fMRI Study*. Pain, 2016.

5. Wolfe, F., et al., *Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia*. J Rheumatol, 2011. **38**(6): p. 1113-22.
6. Basu, N., et al., *Neurobiological features of fibromyalgia are also present among rheumatoid arthritis patients*. Arthritis Rheumatol, 2018.
7. Napadow, V., et al., *Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity*. Arthritis Rheum, 2010. **62**(8): p. 2545-55.
8. Brummett, C.M., et al., *Survey Criteria for Fibromyalgia Independently Predict Increased Postoperative Opioid Consumption after Lower-extremity Joint Arthroplasty: A Prospective, Observational Cohort Study*. Anesthesiology, 2013. **119**(6): p. 1434-43.
9. Janda, A.M., et al., *Fibromyalgia Survey Criteria Is Associated with Increased Postoperative Opioid Consumption in Women Undergoing Hysterectomy*. Anesthesiology, 2015.
10. Brummett, C.M., et al., *Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty*. Arthritis Rheumatol, 2015.
11. Dave, A.J., et al., *The association of pre-operative body pain diagram scores with pain outcomes following total knee arthroplasty*. Osteoarthritis Cartilage, 2017. **25**(5): p. 667-675.
12. Harte, S.E., R.E. Harris, and D.J. Clauw, *The neurobiology of central sensitization*. Journal of Applied Biobehavioral Research, 2018. **23**(2): p. e12137.
13. Woolf, C.J., *Central sensitization: implications for the diagnosis and treatment of pain*. Pain, 2011. **152**(3 Suppl): p. S2-15.
14. Kosek, E. and G. Ordeberg, *Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief*. Pain, 2000. **88**(1): p. 69-78.
15. Brummett, C.M., et al., *Preliminary Validation of the Michigan Body Map (MBM)*. Pain, 2016.
16. Keller, S., et al., *Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain*. Clin J Pain, 2004. **20**(5): p. 309-18.
17. Cella, D., et al., *The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years*. Med Care, 2007. **45**(5 Suppl 1): p. S3-S11.
18. Rosenstiel, A.K. and F.J. Keefe, *The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment*. Pain, 1983. **17**(1): p. 33-44.
19. Woolf, C.J. *Pain amplification—A perspective on the how, why, when, and where of central sensitization*. Journal of Applied Biobehavioral Research, 2018. **0**(0): p. e12124.
20. Clauw, D.J. and P. Katz, *The Overlap Between Fibromyalgia and Inflammatory Rheumatic Disease: When and Why Does it Occur?* J Clin Rheumatol, 1995. **1**(6): p. 335-42.
21. Hench, P.K., *Secondary fibrositis*. American Journal of Medicine, 1986. **81**(3A): p. 60-62.
22. Grace, P.M., et al., *Pathological pain and the neuroimmune interface*. Nature reviews. Immunology, 2014. **14**: p. 217-31.
23. Schrepf, A., et al., *A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis*. Nature Communications, 2018: p. In Press.
24. DeSantana, J.M., K.M. da Cruz, and K.A. Sluka, *Animal models of fibromyalgia*. Arthritis Res Ther., 2013. **15**(6): p. 222.
25. Aaron, L.A., M.M. Burke, and D. Buchwald, *Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder*. Archives of Internal Medicine, 2000. **160**(2): p. 221-227.
26. Maixner, W., et al., *Overlapping Chronic Pain Conditions: Implications for Diagnosis and Classification*. J Pain, 2016. **17**(9 Suppl): p. T93-T107.
27. Arnold, L.M., et al., *Family study of fibromyalgia*. Arthritis Rheum, 2004. **50**(3): p. 944-52.

28. Geisser, M.E., et al., *A psychophysical study of auditory and pressure sensitivity in patients with fibromyalgia and healthy controls*. J.Pain, 2008. **9**(5): p. 417-422.
29. Geisser, M.E., et al., *Comorbid somatic symptoms and functional status in patients with fibromyalgia and chronic fatigue syndrome: sensory amplification as a common mechanism*. Psychosomatics, 2008. **49**(3): p. 235-42.
30. Lopez-Sola, M., et al., *Towards a neurophysiological signature for fibromyalgia*. Pain, 2017. **158**(1): p. 34-47.
31. Lopez-Sola, M., et al., *Altered functional magnetic resonance imaging responses to nonpainful sensory stimulation in fibromyalgia patients*. Arthritis Rheumatol, 2014. **66**(11): p. 3200-9.
32. Tiseo, P.J., et al., *Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee*. Pain, 2014. **155**(7): p. 1245-1252.
33. Cohen, E. and Y.C. Lee, *A Mechanism-Based Approach to the Management of Osteoarthritis Pain*. Curr Osteoporos Rep, 2015. **13**(6): p. 399-406.

## Figure Legends

### **Figure 1. Smoothed group trajectories of the 2011 FM Survey Score following surgery.**

Individual trajectories are shown in light gray. Colors on the body map correspond to percentage changes in each group showing improvement in each region. Regions are adapted from the regional pain definitions of the 2016 Fibromyalgia Survey criteria. Shaded regions show 95% confidence intervals.

### **Figure 2. Smoothed trajectories showing the probability of surgical pain from pre-surgery to month 6.** Significant differences at week 2, month1, and month 3 are shown with p values.

Individual data points are shown as triangles. Shaded regions show 95% confidence intervals.

**Table 1. Demographic and symptom information at baseline for Worsen/Same and Improve groups.**

	Worsen/Same		Improve		t	df	p
	Mean (95% CI)	SD	Mean (95% CI)	SD			
age	61.75 (58.98, 64.52)	9.54	63.61 (61.58, 65.63)	10.31	-1.054	148	.294
Widespread Pain Index (0-19)	2.75 (2.18, 3.32)	1.95	2.40 (2.06, 2.74)	1.74	1.100	148	0.273
Michigan Body Map non-surgical sites	3.83 (2.89, 4.78)	3.26	3.66 (3.08, 4.23)	2.93	0.332	148	0.741
Symptom Severity Index	4.92 (4.32, 5.52)	2.07	4.33 (3.94, 4.73)	2.03	1.633	148	0.105
FM Survey Score	7.67 (6.82, 8.51)	2.93	6.74 (6.25, 7.22)	2.49	2.020	148	0.045
Fatigue	11.88 (10.97, 12.78)	3.11	10.36 (9.65, 11.07)	3.61	2.499	148	0.014
Depression	6.96 (6.07, 7.84)	2.99	5.57 (5.11, 6.04)	2.37	3.013	145	0.003
Sleep Disturbance	26.91 (25.04, 28.79)	6.39	26.45 (25.14, 27.76)	6.57	0.399	144	0.690
Physical Function	13.98 (13.04, 14.92)	3.25	13.09 (12.45, 13.73)	3.23	1.571	147	0.118
Pain Catastrophizing	5.46 (3.62, 7.30)	6.19	4.00 (3.07, 4.93)	4.68	1.571	144	0.118
Brief Pain Inventory Pain Severity (Overall)	4.85 (4.13, 5.58)	2.49	4.72 (4.19, 5.25)	2.70	0.290	148	0.772
Pain Severity (Surgical Site)	6.90 (6.39, 7.40)	1.75	6.23 (5.88, 6.58)	1.76	2.162	148	0.032
	frequency (%)		frequency (%)		$\chi^2$		p

	2 (4)		3 (3)		.15 2		.65 5 <sup>a</sup>
FM positive							
	33 (69)		59 (58)		1.6 37	1	.20 1
Gender (Female)							
	25 (52)		40 (39)		2.2 0	1	.13 8
Surgical cohort (knee)							

<sup>a</sup> Fisher's Exact Test.



**Table 2. Fixed effects for models of change in FM total scores, non-surgical pain, and symptom severity index.**

<b>Variable</b>	<b>Estimate</b>	<b>S.E.</b>	<b>DF</b>	<b>t</b>	<b>p</b>
<b>FM total scores</b>					
Intercept	5.997	1.055	173.4	5.685	< .001
Time	-0.016	0.141	369.5	-0.114	0.910
Time <sup>2</sup>	1.071	0.159	426.5	6.756	< .001
Age	-0.011	0.016	147	-0.675	0.501
Surgical Cohort (hip)	-0.250	0.317	148	-0.787	0.432
Group (Improve)	-0.018	0.514	239	-0.034	0.973
Time X Group	-1.432	0.170	369.1	-8.402	< .001
Time <sup>2</sup> X Group	-0.394	0.192	426.1	-2.059	0.040
<b>non-surgical site pain</b>					
Intercept	3.283	0.993	179.1	3.306	0.001
Time	-0.065	0.171	149.3	-0.377	0.706
Time <sup>2</sup>	0.547	0.159	280.96	3.442	0.001
Age	-0.017	0.014	145.51	-1.177	0.241
Surgical Cohort (hip)	0.586	0.296	146.59	1.983	0.049
Group (Improve)	-0.195	0.513	225	-0.381	0.704
Time X Group	-0.810	0.207	149.02	-3.908	< .001
Time <sup>2</sup> X Group	-0.008	0.192	280.54	-0.044	0.965
<b>Symptom Severity Index</b>					
Intercept	3.881	0.818	169.1	4.746	< .001
Time	0.149	0.101	385.4	1.468	0.143
Time <sup>2</sup>	0.699	0.114	427.6	6.109	< .001
Age	-0.004	0.012	146.4	-0.328	0.743
Surgical Cohort (hip)	-0.571	0.248	147.3	-2.307	0.022
Group (Improve)	0.284	0.383	234.5	0.743	0.458
Time X Group	-1.035	0.123	385.1	-8.441	< .001
Time <sup>2</sup> X Group	-0.369	0.138	427.3	-2.671	0.008

The quadratic time variable was centered